Market Snapshot

BSE Sensex: 73319.55 0.25%
BSE 500: 32839.65 0.08%
BSE 200: 10347.1 0.11%
BSE 100: 23846.26 0.16%
BSE BANKEX: 58009.41 0.22%
BSE IT: 29288.17 2.42%
Nifty 50: 22713.1 0.15%
Nifty 500: 20938.35 0.02%
Nifty 200: 12728 0.06%
Nifty 100: 23304.2 0.14%
Nifty Midcap 100: 53677.05 -0.26%
Nifty Small 100: 15650.5 -0.38%
Nifty IT: 30441.45 2.60%
Nifty PSU Bank: 8134.4 -0.37%

News:

Vikran Engineering bags LoAs w...
Bajaj Housing Finance clocks 2...
Dabur India expects domestic b...
Kernex Microsystems bags Rs 91...
J&K Bank?s gross advances grow...

Aarti Drugs Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

02 Apr 2026 | 03:59 PM

352.05

4.75 (1.37%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

2.77%

Return (1Y)

Beaten BSE Healthcare by 2.17%
More Volatile

2.66%

Standard Deviation (1Y)

Higher than BSE Healthcare by 1.76%
Not so consistent

5/12

Months

underperformed BSE Healthcare
AxisDirect View

52 Week High-Low

575

312

News & Announcements

Aarti Drugs gains as arm incorporates step-down subsidiary in Chile
32 days ago

Aarti Drugs gains as arm incorporates step-down subsidiary in Chile

04 - Mar - 2026 12:00 | 32 days ago

With this incorporation, Tripharma Chile SpA becomes a step-down subsidiary of Aarti Drugs. The newly formed entity has been established to market formulation drugs and participate in government tenders as well as the private pharmaceutical market in Chile. The business activities of the new subsidiary are aligned with those of its holding companies.
The cost of subscription stands at 1,000,000 Chilean pesos towards share capital contribution, comprising 1,000,000 shares. The entire share capital of Tripharma Chile SpA will be held by Pinnacle Chile SpA, making it a wholly owned step-down subsidiary of the company.
Aarti Drugs was established in the year 1984 and forms part of the $6 billion Aarti Group of Industries. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates and speciality chemicals and produces formulations with its wholly-owned subsidiary, Pinnacle Life Science.
The company reported a 9.4% increase in consolidated net profit to Rs 40.54 crore on an 8.1% rise in net sales to Rs 601.71 crore in Q3 FY26 as compared with Q3 FY25.
Powered by Capital Market - Live News
Board of Aarti Drugs recommends interim dividend
60 days ago

Board of Aarti Drugs recommends interim dividend

04 - Feb - 2026 12:00 | 60 days ago

Aarti Drugs announced that the Board of Directors of the Company at its meeting held on 3 February 2026, inter alia, have recommended the interim dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.
Powered by Capital Market - Live News
Aarti Drugs consolidated net profit rises 9.42% in the December 2025 quarter
60 days ago

Aarti Drugs consolidated net profit rises 9.42% in the December 2025 quarter

04 - Feb - 2026 12:00 | 60 days ago

Net profit of Aarti Drugs rose 9.42% to Rs 40.54 crore in the quarter ended December 2025 as against Rs 37.05 crore during the previous quarter ended December 2024. Sales rose 8.10% to Rs 601.71 crore in the quarter ended December 2025 as against Rs 556.60 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 601.71 556.60 8

OPM % 9.15 11.09 -

PBDT 46.97 64.56 -27

PBT 29.02 50.76 -43

NP 40.54 37.05 9

Powered by Capital Market - Live News
Aarti Drugs standalone net profit declines 12.17% in the December 2025 quarter
60 days ago

Aarti Drugs standalone net profit declines 12.17% in the December 2025 quarter

04 - Feb - 2026 12:00 | 60 days ago

Net profit of Aarti Drugs declined 12.17% to Rs 33.84 crore in the quarter ended December 2025 as against Rs 38.53 crore during the previous quarter ended December 2024. Sales rose 2.77% to Rs 528.80 crore in the quarter ended December 2025 as against Rs 514.54 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 528.80 514.54 3

OPM % 8.00 11.71 -

PBDT 36.58 64.05 -43

PBT 21.71 52.03 -58

NP 33.84 38.53 -12

Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Aarti Drugs Ltd has decreased by -19.91% since past 3 Months
FII shareholding in Aarti Drugs Ltd has decreased by -5.78% since past 1 Year
MF shareholding in Aarti Drugs Ltd has increased by 28.95% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	601.71	556.60	8
OPM %	9.15	11.09	-
PBDT	46.97	64.56	-27
PBT	29.02	50.76	-43
NP	40.54	37.05	9

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	528.80	514.54	3
OPM %	8.00	11.71	-
PBDT	36.58	64.05	-43
PBT	21.71	52.03	-58
NP	33.84	38.53	-12

General Notifications

My Notifications

Research Notifications

Aarti Drugs Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

352.05 4.75 (1.37%)

News & Announcements

Price vs Volume

Stock Trivia

Aarti Drugs Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

352.05

4.75 (1.37%)